This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.
June 2022 in “Journal of The European Academy of Dermatology and Venereology” This study reports no results yet and only indicates an ongoing randomized placebo-controlled trial investigating the effects of microneedling combined with topical dutasteride solution for treating androgenetic alopecia.
September 2024 in “Journal of the American Academy of Dermatology” This study found that a new compounded topical solution for alopecia was clinically tolerable and did not cause irritation, while also showing potential to enhance hair growth through fibroblast proliferation and gene expression.
7 citations
,
September 2015 in “Actas Dermo-Sifiliográficas” This article reviews the challenges of treating frontal fibrosing alopecia and the potential role of hair transplantation, noting the lack of effective medical treatments and uncertainty surrounding transplant outcomes.
This review discusses the criteria for evaluating treatments for androgenetic alopecia and emphasizes the importance of shared decision-making, noting no treatment currently meets all desired criteria of efficacy, safety, affordability, and ease of use.